Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

Exclusion Criteria

• •History of or active periocular, ocular, or intraocular infection.
• •Previous use of verteporfin photodynamic therapy (PDT) or any ocular anti-angiogenic therapy (eg, aflibercept, bevacizumab, ranibizumab, pegaptanib), approved or investigational, for the treatment of neovascular AMD or previous therapeutic radiation in the region.
• •Prior use of ocular anti-VEGF agents for neovascular eye diseases other than AMD.
• •Macular hemorrhage that involves the center of fovea in the study eye.
• •Any prior or current systemic or ocular treatment (including surgery) for neovascular AMD in the study eye.
• •Treatment with ocular corticosteroid injections or implants within 6 months in the study eye.
• •History or evidence of eye surgery: Pars plana vitrectomy, Submacular surgery or other surgical interventions for AMD, Incisional glaucoma surgery or Cataract or refractive surgery within the last 3 months.
• •AMD in the non-study eye that requires anti-VEGF treatment.